Taiwan · Delayed Price · Currency is TWD GlycoNex Incorporation Company Description
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan.
The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage.
It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and SEA (Aflibercept), a vascular endothelial growth factor binding fusion protein, currently under lead optimization stage for the treatment of ophthalmology and oncology.
The company was incorporated in 2001 and is based in New Taipei City, Taiwan.
| Country | Taiwan |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mei-Chun Yang |
Contact Details
Address: No. 97, Xintai 5th Road New Taipei City, 221 Taiwan | |
| Phone | 886 2 2697 4168 |
| Website | glyconex.com.tw |
Stock Details
| Ticker Symbol | 4168 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004168000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mei-Chun Yang | President, Chief Executive Officer and Manager |
| Yaohua Lu | Deputy GM and Corporate Governance Officer |
| Ti-Fen Wu | Chief Financial Officer and Accounting Supervisor |